Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033714 | 0.86 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1GRIN2D | |
| SCHEMBL21341551 | 0.83 | GRIN2D (0.32) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL23075984 | 0.80 | CRHBP (0.37) | — | |
| SCHEMBL8260611 | 0.74 | GRIN2D (0.35) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL8260601 | 0.74 | GRIN2D (0.32) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL16554027 | 0.74 | GRIN2D (0.32) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL6120503 | 0.73 | OPRM1 (0.38) | OPRM1OPRD1OPRK1OPRL1GRIN2D | |
| SCHEMBL24974302 | 0.71 | GRIN2D (0.36) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL13093380 | 0.71 | — | — | |
| SCHEMBL16117658 | 0.70 | GRIN2D (0.39) | OPRM1GRIN2DGRIN3BCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124772-B2 | Intermediate products for producing oxazolidinone-quinolone hybrids | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090306389-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2009-12-10 | — | — | US | disclosed |
| US-7557214-B2 | Intermediate products for producing oxazolidinone-quinolone hybrids | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2009-07-07 | — | — | US | disclosed |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | MORPHOCHEM AKTIEGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306389-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | OXA1L, NQO1, NQO2 | OPRM1 2153/4885OPRD1 1352/4885OPRK1 2157/4885 |
| US-20070004769-A1 | Intermediate products for producing oxazolidinone-quinolone hybrids | OXA1L, NQO1, NQO2 | OPRM1 2153/4885OPRD1 1352/4885OPRK1 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.